Close search

DoseMe Debut US Offering for ASHP Summer 2017

DoseMe Debut US Offering for ASHP Summer 2017
1 Jun 2017 Media Release

Australian founded software company DoseMe will launch US precision dosing clinical decision support solution – DoseMeRx – at the upcoming American Society of Health-System Pharmacists (ASHP) Summer meeting.

DoseMeRx is built on the same algorithms that underpin the DoseMe platform of real-time dose-related clinical decision support with tailored enhancements for the U.S. health and regulatory environment.

“At the core of our business is pairing complex algorithms with a simple, app-based user interface to allow a clinician to quickly and accurately determine the right dose for each patient.

DoseMeRx is specialized for the rapid pace of automation adoption of health information systems in U.S health care organizations,” said Chief Executive Officer, Charles Cornish.

DoseMe is the first Australian founded precision dosing software company to establish a presence in the United States. Strategically, DoseMe has set up offices in two leading health-hub cities of Houston (based out of Texas Medical Center) and Minneapolis (Medical Alley) to serve the US market.

“The American Society of Health-System Pharmacists Summer Meeting is a natural fit to showcase DoseMeRx and network with potential partners and thought leaders.

It is a significant milestone for DoseMe and our focus is to collaborate with clinicians to deliver safe dose individualisation decision support to help them make the best decisions for patient care and deliver better outcomes for Americans,” said Cornish.

ASHP Summer Meeting is being held at the Minneapolis Convention Center in Minneapolis, MN from June 4-6 2017. DoseMeRx will be conducting live demonstrations at booth #835.

About DoseMeRx

DoseMeRx is a precision dosing software designed for clinicians that uses Bayesian dosing methods to predict the optimal dose of drugs monitored by Therapeutic Drug Monitoring. It is unique support software that leverages clinically validated pharmacokinetic drug models, patient characteristics, patient genotype information and exact patient responses to the drug dosed (via drug concentrations) to guide dose optimization. It’s simplicity and portability means Bayesian dosing benefits can be brought to every bedside.

View PulseIT article. 

Privacy policy | Copyright © 2012 - 2017 DoseMe Pty Ltd. All Rights Reserved. DoseMe® is a registered trademark of DoseMe Pty Ltd. DoseMeRx℠ and DoseMe℞℠ are service marks of DoseMe LLC.